



IN THE UNITED STATES PATENT AND TRADEMARK OFFICE

In Re the Application of:

KIEFER et al.

Serial No.: 09/633,200

Filed: August 7, 2000

Atty. File No.: 4588-1-1-DIV4

For: "METHODS AND COMPOSITIONS  
FOR DETECTING CDN APOPTOSIS  
MODULATING PROTEINS"  
(as amended)


Assistant Commissioner for Patents  
Washington, D.C. 20231

) Group Art Unit: 1642

) Examiner: Hunt, J.

SUBMISSION OF REFERENCES

1642  
NOV 26 2002  
RECEIVED  
TECH CENTER 1600/2900  
D#12

CERTIFICATE OF MAILING	
I HEREBY CERTIFY THAT THIS CORRESPONDENCE IS BEING DEPOSITED WITH THE UNITED STATES POSTAL SERVICE AS FIRST CLASS MAIL IN AN ENVELOPE ADDRESSED TO THE COMMISSIONER FOR PATENTS, WASHINGTON, DC 20231 ON SHERIDAN ROSS P.C.	
BY:	

Dear Sir:

Pursuant to the Examiner's request in the Office Action dated February 13, 2002 and the Office Action dated August 26, 2002, enclosed are copies of the references cited on Applicants' 1449 form for the above-identified application, which was filed March 16, 2001. Pursuant to 37 CFR 1.98(d), copies of the references were not submitted on March 16, 2001, since the copies should have been of record in the parent application. However, since the Patent Office was unable to locate the references, copies are now provided for the Examiner's convenience and consideration.

Applicants respectfully request that the Examiner consider the enclosed references and initial and date Applicants' 1449 form. Applicants note that the only reference for which a copy is not enclosed is item 55 (Meyn, *Cancer Genet.*, 53:(Abstract No. 1529), 1993). Applicants were unable to locate or obtain a copy of the reference at this time.

Since the original 1449 was timely and properly filed, no fees are believed to be due in connection with this submission, but if fees are due, please debit Deposit Account No. 19-1970.


Respectfully submitted,

SHERIDAN ROSS P.C.

By:

  
Angela K. Dallas  
Registration No. 42,460  
1560 Broadway, Suite 1200  
Denver, CO 80202-5141  
(303) 863-9700

Date: November 21, 2002



EXAMINER 1449	U.S. DEPARTMENT OF COMMERCE PATENT AND TRADEMARK OFFICE		ATTY. DOCKET NO. 4588-1-1-DIV4	SERIAL NO. 09/633,200
INFORMATION DISCLOSURE STATEMENT (Use several sheets if necessary)			APPLICANT KIEFER et al.	
			FILING DATE August 7, 2000	GROUP ART

## U.S. PATENT DOCUMENTS

*EXAMINER INITIAL		DOCUMENT NUMBER	DATE	NAME	CLASS	SUB CLASS	FILING DATE IF APPROP.

## FOREIGN PATENT DOCUMENTS

		DOCUMENT NUMBER	DATE	COUNTRY	CLASS	SUB CLASS	TRANSLATION	
							YES	NO
*	1	WO 93/04169	3/4/93	PCT				
*	2	WO 94/00572	1/6/94	PCT				
*	3	WO 95/00160	1/5/95	PCT				
*	4	WO 95/00642	1/5/95	PCT				
*	5	WO 95/05738	3/2/95	PCT				
*	6	WO 95/05750	3/2/95	PCT				
*	7	WO 95/15084	6/8/95	PCT				
*	8	WO 96/05232	2/22/96	PCT (Abstract)				
*	9	WO 96/33416	10/24/96	PCT				
*	10	WO 96/35951	11/14/96	PCT (Abstract)				

## OTHER ART (Including Author, Title, Date, Pertinent Pages, etc.)

*	11	Ameisen et al., <i>Immunol. Today</i> , 12:102-105 (1991)
*	12	Barr, <i>Transgenesis</i> , (1992) Murray, J.A.H., ed., Wiley & Sons, New York, pp. 55-79
*	13	Boise et al., <i>Cell</i> , 74:597-608 (1993)
	14	Bowie et al., <i>Science</i> , 247:1306-1310 (1990)
	15	Brown, "News Media, Researchers 'Oversold' Gene Therapy, Advisory Panel Says," <i>The Washington Post</i> (1995)
	16	Buckel, <i>Trends Pharm. Sci.</i> , 17:450-456 (1996)
	17	Callard et al., <i>The Cytokine FactBook</i> , Academic Press, London, p. 31 (1994)
	18	Cazals-Hatem et al., <i>Biochimica et Biophysica Acta</i> , 1132:109-113 (1992)

EXAMINER	DATE CONSIDERED
*EXAMINER: Initial if reference considered, whether or not citation is in conformance with MPEP 609; Draw line through citation if not in conformance and not considered. Include copy of this form with next communication to applicant.	

 TECH CENTER 1600/2000  
NOV 26 2002  
RECEIVED



FORM PTO-1449 U.S. DEPARTMENT OF COMMERCE PATENT AND TRADEMARK OFFICE		ATTY. DOCKET NO. 4588-1-1-DIV4	SERIAL NO. 09/633,200
INFORMATION DISCLOSURE STATEMENT (Use several sheets if necessary)		APPLICANT KIEFER et al.	
		FILING DATE August 7, 2000	GROUP ART

*	19	Chen-Levy et al., <i>Mol. Cell. Biol.</i> , 9:701-710 (1989)
*	20	Cherif et al., <i>Hum. Genet.</i> , 93:1-6 (1994)
*	21	Chittenden et al., <i>Nature</i> , 347:733-736 (1995)
*	22	Chittenden et al., <i>EMBO J.</i> , 14:5589-5596 (1995)
*	23	Cleary et al., <i>Cell</i> , 47:19-28 (1986)
	24	Coghlan, <i>Focus</i> , 148:14-15 (1995)
*	25	Cohen et al., <i>Ann. Rev. Immunol.</i> , 10:267-293 (1992)
	26	Dorin et al., <i>Gene Ther.</i> , 3:797-801 (1996)
*	27	Duke et al., <i>Lymphokine Res.</i> , 5:289-299 (1986)
	28	Dzau et al., <i>Proc. Natl. Acad. Sci. USA</i> , 93:11421-11425 (1996)
*	29	Edgington et al., <i>Biotechnol.</i> , 11:787-792 (1993)
*	30	Farrow et al., <i>Nature</i> , 374:731-733 (1995)
*	31	Feinberg et al., <i>Anal. Biochem.</i> , 137:266-267 (1984)
*	32	Foroud et al., <i>Am. J. Hum. Genet.</i> , 49:1263-1279 (1991)
*	33	Gershenson et al., <i>FASEB J.</i> , 6:2450-2455 (1992)
	34	Grossman et al., <i>Nat. Genet.</i> , 6:323-324 (1994)
*	35	Henderson et al., <i>Proc. Natl. Acad. Sci. USA</i> , 90:8479-8483 (1993)
*	36	Hickish et al., <i>Cancer Research</i> , 54:2808-2811 (1994)
*	37	Hockenberry et al., <i>Nature</i> , 348:334-336 (1990)
*	38	Hockenberry et al., <i>Cell</i> , 75:241-251 (1993)
*	39	Jacobson et al., <i>Nature</i> , 361:365-369 (1993)
*	40	Kanter et al., <i>Biochem. Biophys. Res. Commun.</i> , 118:392-399 (1984)
*	41	Kapp et al., <i>Am. J. Hum. Genet.</i> , 51:45-54 (1992)
	42	Keating et al., <i>Bone Marrow Purging and Processing</i> , 333:491-498 (1990)
*	43	Kennedy, <i>Cancer Res.</i> , 54:1999s-2005s (1994)
*	44	Khati et al., <i>Neurology</i> , 43:1131-1137 (1993)
*	45	Kiefer et al., <i>Biochem. Biophys. Res. Commun.</i> , 176:219-225 (1991)
*	46	Kiefer et al., <i>Nature</i> , 374:736-739 (1995)
*	47	Klein, <i>J. Clin. Apheresis</i> , 9:139-141 (1994)
*	48	Kruman et al., <i>J. Cell. Physiol.</i> , 148:267-273 (1991)
*	49	Lam et al., <i>Proc. Natl. Acad. Sci. USA</i> , 91:6569-6573 (1994)

RECEIVED  
NOV 6 2002  
PTO

EXAMINER	DATE CONSIDERED
*EXAMINER: Initial if reference considered, whether or not citation is in conformance with MPEP 609; Draw line through citation if not in conformance and not considered. Include copy of this form with next communication to applicant.	



FORM PTO-1449		U.S. DEPARTMENT OF COMMERCE PATENT AND TRADEMARK OFFICE	ATTY. DOCKET NO. 4588-1-1-DIV4	SERIAL NO. 09/633,200
INFORMATION DISCLOSURE STATEMENT (Use several sheets if necessary)		APPLICANT KIEFER et al.		
		FILING DATE August 7, 2000	GROUP ART	

*	50	Lehrach et al., <i>Biochem.</i> , <b>16</b> :4743-4751 (1977)
*	51	Lewin, <i>Science</i> , <b>237</b> :1570 (1987)
	52	Marshall, <i>Science</i> , <b>269</b> :1050-1055 (1995)
*	53	McDonnell et al., <i>Nature</i> , <b>349</b> :254-256 (1991)
*	54	McKearn et al., <i>Proc. Natl. Acad. Sci. USA</i> , <b>82</b> :7414-7418 (1985)
*	55	Meyn, <i>Cancer Genet.</i> , <b>53</b> :(Abstract no. 1529) (1993)
*	56	Monaghan et al., <i>J. Histochem. Cytochem.</i> , <b>40</b> :1819-1825 (1992)
	57	Ngo et al., <i>The Protein Folding Problem and Tertiary Structure Prediction</i> , Merz et al., eds., Birkhauser, Boston, PP. 491-495 (1994)
	58	Norrby et al., <i>APMIS</i> , <b>105</b> :417-437 (1997)
*	59	Nuñez et al., <i>J. Immunol.</i> , <b>144</b> :3602-3610 (1990)
*	60	Oltvai et al., <i>Cell</i> , <b>74</b> :609-619 (1993)
	61	Orkin et al., <i>Report and Recommendations of the Panel to Assess the NIH Investment in Research on Gene Therapy</i> (1995)
*	62	Orr et al., <i>Nature Genetics</i> , <b>4</b> :221-226 (1993)
*	63	Pearson et al., <i>Virology</i> , <b>160</b> :151-161 (1987)
*	64	Pinkel et al., <i>Proc. Natl. Acad. Sci. USA</i> , <b>85</b> :9138-9142 (1988)
*	65	Reeck, <i>Cell</i> , <b>50</b> :667 (1987)
*	66	Reed et al., <i>Cancer Res.</i> , <b>50</b> :6565-6570 (1990)
*	67	Sanger et al., <i>Proc. Natl. Acad. Sci. USA</i> , <b>74</b> :5463-5467 (1977)
*	68	Sentman et al., <i>Cell</i> , <b>67</b> :879-888 (1991)
*	69	Sheppard et al., <i>J. AIDS</i> , <b>5</b> :143-147 (1992)
*	70	Strasser et al., <i>Cell</i> , <b>67</b> :889-899 (1991)
*	71	Tarodi et al., <i>Virology</i> , <b>201</b> :404-407 (1994)
*	72	Thomas, <i>Proc. Natl. Acad. Sci. USA</i> , <b>77</b> :5201-5205 (1980)
*	73	Tomei et al., <i>Biochem. Biophys. Res. Commun.</i> , <b>155</b> :324-331 (1988)
*	74	Tsujimoto et al., <i>Science</i> , <b>226</b> :1097-1099 (1984)
*	75	Veis et al., <i>Cell</i> , <b>75</b> :229-240 (1993)
*	76	Viegas-Péquignot, <i>In Situ Hybridization. A Practical Approach</i> , D.G. Wilkinson, ed., IRL Press, Oxford, pp. 137-159
*	77	Williams et al., <i>Cell</i> , <b>74</b> :777-779 (1993)
*	78	Wyllie, <i>Nature</i> , <b>284</b> :555-556 (1980)
*	79	Yonehara et al., <i>J. Exp. Med.</i> , <b>169</b> :1747-1756 (1989)
*	80	Zapf et al., <i>J. Biol. Chem.</i> , <b>265</b> :14892-14898 (1990)

RECEIVED  
NOV 26 2002  
TECHNICAL INFORMATION CENTER  
U.S. PATENT AND TRADEMARK OFFICE

EXAMINER	DATE CONSIDERED
*EXAMINER: Initial if reference considered, whether or not citation is in conformance with MPEP 609; Draw line through citation if not in conformance and not considered. Include copy of this form with next communication to applicant.	

O I P E C 16  
NOV 25 2002  
PATENT & TRADEMARK OFFICE

U.S. DEPARTMENT OF COMMERCE PATENT AND TRADEMARK OFFICE		ATTY. DOCKET NO. 4588-1-1-DIV4	SERIAL NO. 09/633,200
INFORMATION DISCLOSURE STATEMENT (Use several sheets if necessary)			
		APPLICANT KIEFER et al.	
		FILING DATE August 7, 2000	GROUP ART

*	81	Zhu et al., <i>Science</i> , 261:209-211 (1993)
---	----	---

RECEIVED  
TECH CENTER 1600/2900  
NOV 26 2002

EXAMINER	DATE CONSIDERED
<p>*EXAMINER: Initial if reference considered, whether or not citation is in conformance with MPEP 609; Draw line through citation if not in conformance and not considered. Include copy of this form with next communication to applicant.</p>	